User access denied after restriction
Serene Hesri was 25 when she learned she had Hodgkin’s lymphoma. The diagnosis arrived on her birthday, a day that should have been ordinary. Instead, it marked the start of a struggle she never expected.
“It was a lot of shock, and maybe a little denial,” she said. “At 25, you expect to be healthy. Cancer isn’t something you plan for.” The news came after a biopsy confirmed her fears. Hesri had no family history of the disease, so the situation felt unfamiliar and overwhelming.
From remission to relapse in three months
After initial treatment, Hesri entered remission. Three months later, the cancer returned. The relapse destroyed the fragile hope she had started to rebuild. “It made me feel like my hope was being taken away again,” she said.
Her doctors offered new options. During her first remission, Hesri had begun asking more questions about her care. That curiosity led to a discussion about clinical trials—something she hadn’t considered before. “If standard treatment hadn’t worked the first time, I worried it wouldn’t work the second time either,” she said. She needed a stronger option.
Many people view clinical trials as a last resort, a risky experiment. Hesri had heard the same concerns: that participants might be treated like test subjects or receive a placebo. But her oncologist shifted her thinking. When she asked what he would do if she were his daughter, he answered without hesitation. “If you were my daughter, I would tell you to do this,” he said.
His words stayed with her. Hesri joined the trial, and five years later, she remains cancer-free. The experience changed how she sees medical research—not as a desperate choice, but as a real opportunity.
“I felt more cared for than I could have expected”
The trial involved more than just treatment. It included detailed monitoring and a level of attention she hadn’t experienced before. “They wanted the trial to work, and they wanted me to thrive,” Hesri said. Follow-up visits continued even after remission, with pulmonary tests and other checks to track her health. “That extra care isn’t something everyone gets with standard treatment.”
Related: Sorry, you have been blocked
Now, Hesri pushes for earlier discussions about clinical trials. When she was first diagnosed, the idea never came up. It was only after relapse that the option was mentioned. “People have a lot of wrong ideas about what trials mean,” she said. “I’d like to see them offered as a first choice, not just a last one.”
For patients facing a new diagnosis or recurrence, her advice is straightforward: ask questions, get second opinions, and don’t accept the first answer as the only one. “When you talk to multiple doctors, you feel more sure about your decisions,” she said. “Cancer is frightening, but help exists.”
The trial helped Hesri and also advanced research that could improve future treatments. That double impact—personal and shared—is what she wants others to recognize. “I truly felt lucky to be part of it,” she said.
Hesri’s experience reflects a common issue in how clinical trials are presented. Many patients learn about them too late. Others assume they’re only for those who’ve run out of options. Neither belief is accurate. Trials can provide access to new treatments, often with more careful oversight than regular care.
For Hesri, the trial became a defining moment. It wasn’t just about staying alive—it was about feeling valued, supported, and connected to something bigger. “Don’t hesitate to ask,” she said. “You might find an unexpected opportunity.”
Her journey also showed how emotional resilience plays a role in recovery. The trial’s structure gave her stability during uncertainty, much like the grounding effect of time spent in nature.
